Early results reveal how a single‑cell spatial platform maps stromal barriers that limit antibody delivery and target engagement in human solid tumors.

Researchers found that lowering MHC I can expose cancerous or foreign cells to CD4+ T cell attack, reshaping assumptions ...

In multiple myeloma, plasma cells proliferate uncontrollably in the bone marrow, disrupting the growth of healthy blood-forming cells. If the disease recurs after treatment or fails to respond, CAR ...

Cancer cells undergo physically constraining processes, such as intravasation, extravasation, and tissue infiltration, that lead to acute mechanical stress. How mechanical confinement rewires the ...

A targeted antibody‑drug conjugate shrinks tumors and slows progression in recurrent uterine cancer by ferrying potent ...

Researchers from the Icahn School of Medicine at Mount Sinai have discovered a promising new way to improve CAR-T cell ...

Many cancers can be treated by administering DNA-damaging agents, such as platinum-based chemotherapy, because the resulting ...

New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer.

Researchers have successfully used repurposed cancer drugs to target dormant breast cancer cells, aiding in the delay or prevention of recurrence, according to a study published Sept. 2 in Nature ...

Cancer cells can brainwash their neighbors. Like the CIA deploying secret agents to turn an enemy, tumors use a similar strategy to manipulate nearby cells. The tumors’ agents are mitochondria, the ...

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.